» Articles » PMID: 38558839

Risk of Candidiasis Associated with Interleukin-17 Inhibitors: Implications and Management

Abstract

The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining mucosal barriers and coordinating the immune response against species. The observational data and clinical trials demonstrate the increased incidence of candidiasis in individuals treated with IL-17 inhibitors. Brodalumab and bimekizumab pose a greater risk than secukinumab in eliciting candidiasis, whereas the data regarding ixekizumab are equivocal. Higher doses and prolonged treatment duration of IL-17 inhibitors increase the risk of candidiasis by compromising the immune response against species. Prior to prescribing IL-17 inhibitors, healthcare professionals should comprehensively evaluate patients' medical histories and assess their risk factors. Patients should be educated on the signs and symptoms of candidiasis to facilitate early detection and intervention. Future research should focus on identifying the risk factors associated with candidiasis in patients receiving IL-17 inhibitors. Prospective studies and long-term surveillance are required to explore the impact of specific inhibitors on the incidence and severity of candidiasis and to evaluate the effectiveness of combination therapies, such as concurrent use of IL-17 inhibitors and prophylactic antifungal agents.

Citing Articles

Deciphering the role of IL17RA in psoriasis and chronic mucocutaneous candidiasis: shared pathways and distinct manifestations.

Kadhi A, Eid E, Massaad M, El-Rassy I, Khoury D, Shimomura Y Front Immunol. 2025; 15:1516408.

PMID: 39911581 PMC: 11796622. DOI: 10.3389/fimmu.2024.1516408.


Host-microbe interaction paradigms in acute and recurrent vulvovaginal candidiasis.

MacAlpine J, Lionakis M Cell Host Microbe. 2024; 32(10):1654-1667.

PMID: 39389030 PMC: 11469575. DOI: 10.1016/j.chom.2024.08.018.


The Impact of Oral Microbiome Dysbiosis on the Aetiology, Pathogenesis, and Development of Oral Cancer.

Talapko J, Eric S, Mestrovic T, Stipetic M, Juzbasic M, Katalinic D Cancers (Basel). 2024; 16(17).

PMID: 39272855 PMC: 11394246. DOI: 10.3390/cancers16172997.


Interleukin inhibitors and the associated risk of candidiasis.

Khan S, Bilal H, Khan M, Fang W, Chang W, Yin B Front Immunol. 2024; 15:1372693.

PMID: 38605952 PMC: 11007146. DOI: 10.3389/fimmu.2024.1372693.

References
1.
van der Heijde D, Gensler L, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A . Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020; 79(5):595-604. PMC: 7213320. DOI: 10.1136/annrheumdis-2020-216980. View

2.
Bojang E, Ghuman H, Kumwenda P, Hall R . Immune Sensing of . J Fungi (Basel). 2021; 7(2). PMC: 7914548. DOI: 10.3390/jof7020119. View

3.
Papp K, Merola J, Gottlieb A, Griffiths C, Cross N, Peterson L . Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018; 79(2):277-286.e10. DOI: 10.1016/j.jaad.2018.03.037. View

4.
Berry S, Dossou C, Kashif A, Sharifinejad N, Azizi G, Hamedifar H . The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases. Int Immunopharmacol. 2021; 102:108402. DOI: 10.1016/j.intimp.2021.108402. View

5.
Li Z, Lu G, Meng G . Pathogenic Fungal Infection in the Lung. Front Immunol. 2019; 10:1524. PMC: 6616198. DOI: 10.3389/fimmu.2019.01524. View